Gastrointestinal Cancer Research Program

Eng invited to White House Cancer Moonshot forum

Vanderbilt’s Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.

Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform

Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.

New Physician Spotlight: Cathy Eng

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.